Antiretroviral Therapy

Traditional combined antiretroviral therapy — or cART — and alternative cART were similarly effective in treating HIV-infected pregnant women, with similar rates of vertical transmission, according to a study.

Among patients with HIV on antiretroviral therapy, AKI incidence fluctuated between 2005 and 2015 without significant temporal trends, according to a speaker at ASN Kidney Week.

Integrating medications for opioid use disorder with HIV treatment improves viral suppression and ART adherence among people with both HIV and opioid use disorder, study findings published in Open Forum Infectious Diseases showed.

People living with HIV and experiencing homelessness were less likely to use an integrase inhibitor-based regimen for ART, according to a study conducted in San Francisco.

The International Antiviral Society-USA will host a 2-day virtual course this month titled, “From CROI to the Clinic,” which will feature updates from CROI and information for HIV clinicians.

Over time, people with HIV who received Vemlidy instead of Viread as part of their antiretroviral therapy experienced weight gain and other negative metabolic changes, researchers reported in Annals of Internal Medicine.

Vaccines containing a novel T cell immunogen were safe and highly immunogenic in early-treated people with HIV who discontinued ART, according to study results presented at the Conference on Retroviruses and Opportunistic Infections.

An ART home delivery program significantly increased viral suppression among patients with HIV in South Africa, according to study results presented at the Conference on Retroviruses and Opportunistic Infections.

The median time between when patients enter HIV care to when they receive a prescription for ART decreased by more than 90% between 2005 and 2018, according to a study published in Clinical Infectious Diseases.

In a cohort of patients with HIV, weight gain was linked to the use of certain types of ART, as well as a baseline diagnosis of hypertension, a researcher reported at IDWeek.